Abstract
Prostate cancer is one of the most common cancers in the Western world. It is among the leading causes of cancer related death. While its incidence and survival increased significantly during the last few decades in Denmark, the mortality rate did not change for patients younger than 80 year old. Development of new techniques, such as multiparametric MRI, helps to increase the accuracy of diagnosis. However, a missing link in the diagnostic pathway may result in mistreatment if an acinar adenocarcinoma of prostate is transformed into a neuroendocrine phenotype such as small cell carcinoma.
References
Cookson MS, Roth BJ, Dahm P, et al. (2015) Castration-Resistant Prostate Cancer. AUA Guideline. In AUA Guidelines https://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm. Accessed 27 June 2016
Mottet N, Bellmunt J, Briers E, et al. (2016) Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/. Accessed 27 June 2016
Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 34:22–29
Spiess PE, Pettaway CA, Vakar-Lopez F et al (2007) Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110:1729–1737
Li Z, Sun Y, Chen X et al (2015) P 53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res 13:584–591
Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60
Burchardt T, Burchardt M, Chen MW et al (1999) Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162:1800–1805
Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637
Vlachostergios PJ, Papandreou CN (2015) Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 5:6
Small EJ, Huang J, Youngren J, et al. (2015) Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). 2015 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/152182-156. Accessed 27 June 2016
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wøyen, A.V.T., Laczkó, G., Høyer, S. et al. The Missing Link in the Diagnostic Pathway of Prostate Cancer. Pathol. Oncol. Res. 23, 447–450 (2017). https://doi.org/10.1007/s12253-016-0183-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-016-0183-1